跳至主導覽
跳至搜尋
跳過主要內容
國立陽明交通大學研發優勢分析平台 首頁
English
中文
首頁
人員
單位
研究成果
計畫
獎項
活動
貴重儀器
影響
按專業知識、姓名或所屬機構搜尋
查看斯高帕斯 (Scopus) 概要
張 世慶
教授
醫學系外科學科
電話
65313
電子郵件
scchang3
ym.edu
tw
h-index
h10-index
h5-index
4225
引文
38
h-指數
按照存儲在普爾（Pure）的出版物數量及斯高帕斯（Scopus）引文計算。
1278
引文
22
h-指數
按照存儲在普爾（Pure）的出版物數量及斯高帕斯（Scopus）引文計算。
333
引文
11
h-指數
按照存儲在普爾（Pure）的出版物數量及斯高帕斯（Scopus）引文計算。
2003
2024
每年研究成果
概覽
指紋
網路
研究成果
(141)
類似的個人檔案
(6)
指紋
查看啟用 Shih-Ching Chang 的研究主題。這些主題標籤來自此人的作品。共同形成了獨特的指紋。
排序方式
重量
按字母排序
Keyphrases
Colorectal Cancer
100%
Colorectal Cancer Patients
56%
Microsatellite Instability-high (MSI-H)
35%
Tumor
35%
Metastatic Colorectal Cancer (mCRC)
30%
Overall Survival
26%
Carcinoembryonic Antigen
22%
Chemotherapy
18%
Patients with Colorectal Cancer
18%
Disease-free Survival
16%
Clinical Significance
16%
Colon Cancer
16%
5-year Survival
15%
Right-sided Colon Cancer
15%
Taiwan
14%
Multivariate Analysis
13%
Prognostic Factors
12%
Taipei
12%
Carcinoembryonic Antigen Levels
12%
Gastric Cancer
12%
General Hospital
12%
Curative Surgery
12%
Hypermethylation
12%
Independent Prognostic Factor
11%
Prognostic Value
10%
Lymphovascular Invasion
10%
Lymph Node Metastasis
9%
KRAS mutation
9%
Genetic Modification
9%
Sporadic Colorectal Cancer
8%
Patient Outcomes
8%
BRAF mutation
8%
Cell-free DNA (cfDNA)
8%
Gastric Cancer Patients
8%
Hazard Ratio
8%
Microsatellite Stable
7%
Mutation Spectrum
7%
Colorectal Adenocarcinoma
7%
Cancer-specific Survival
6%
Confidence Interval
6%
Cetuximab
6%
Univariate Analysis
6%
TNM Staging
6%
Carbohydrate Antigen 19-9 (CA19-9)
6%
Stage II Colorectal Cancer
6%
Curative Resection
6%
Elevated Microsatellite Alteration at Selected Tetranucleotide Repeats (EMAST)
6%
Prognostic Biomarker
6%
Molecular Differences
6%
Synchronous Colorectal Cancer
6%
Medicine and Dentistry
Colorectal Carcinoma
99%
Neoplasm
35%
Colon Carcinoma
28%
Disease
27%
Overall Survival
23%
Rectum Cancer
21%
Carcinoembryonic Antigen
18%
Surgery
17%
Chemotherapy
16%
Prognostic Factor
15%
Disease Free Survival
15%
Metastatic Carcinoma
15%
Recurrent Disease
13%
Survival Rate
12%
Metastasectomy
12%
Abdominal Cancer
12%
Microsatellite Instability
11%
Malignant Neoplasm
11%
Gene Mutation
9%
Primary Tumor
9%
Multivariate Analysis
8%
Biological Marker
8%
Lymphovascular Invasion
8%
Liver Metastasis
8%
Lymph Node Metastasis
8%
Lymph Node
7%
Chemoradiotherapy
7%
CA 19-9 Antigen
6%
Metastatic Colorectal Cancer
6%
Proportional Hazards Model
6%
Cell-Free DNA
5%
Colon
5%
Distant Metastasis
5%
Adenocarcinoma
5%
Carcinogenesis
5%
Univariate Analysis
5%
